Brind.
  1. The FDA is reviewing applications for new medical treatments, including a C5 complement inhibitor for IgAN.

CorMedix sought FDA approval for its REZZAYO submission on June 16, 2026.

1 report, 1 independent Updated Jun 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

CorMedix sought FDA approval for its REZZAYO submission on June 16, 2026.

Who's involved

What this event is mainly about
FDA

Keep exploring

Part of

The FDA is reviewing applications for new medical treatments, including a C5 complement inhibitor for IgAN. All 3 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped